Pharmaceuticals company Piramal Pharma announced Q1FY26 results Revenue from Operations stood at Rs 1,934 crore vs Rs 1,951 crore in Q1FY25. Excluding the impact of destocking in one of the large CDMO product, the YoY revenue growth was in early double-digit EBITDA margin at 9% vs 11% in Q1FY25. Impact of inventory destocking, partly offset by improved profitability of the overseas facilities in the CDMO business Net-Debt to EBITDA ratio at 2.6x Best-in-Class Quality Track Record – Successfully closed USFDA inspection at Aurora facility (Canada) with zero observations. Continue to maintain our ‘Zero OAIs’ status since 2011 Sustainability Efforts Yielding Results – Assigned an ESG rating of ‘61’ for FY2024 by NSE Sustainability Ratings and Analytics Limited Nandini Piramal, Chairperson, Piramal Pharma said, “Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business delivered healthy growth, in-line with our expectations, driven by power brands and ecommerce sales. Withstanding the near-term challenges, we believe we are on track to achieve our FY2030 aspirations of becoming a US$2bn revenue company with 25% EBITDA margin and high-teen ROCE.” Result PDF
Conference Call with Piramal Pharma Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.